CA19-9
From Wikipedia, the free encyclopedia
CA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category. While it is not useful to diagnose particular forms of cancer, specifically pancreatic cancer, it may be useful to monitor the results of treatment and to determine whether the disease may be recurring.[1] Other causes for elevated CA19-9 levels include Mirizzi's syndrome and other hepatobiliary diseases.[2] In patients that do not have the Lewis antigen blood type (about 5% of the population), CA19-9 is not elevated in pancreatic cancer even with large tumors because they have a deficiency of fucosyltransferase that is needed to produce CA19-9.[1]
Ca19-9 was discovered in patients with colon cancer and pancreatic cancer in 1981.[3]
[edit] References
- ^ a b Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006). "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer". J. Clin. Oncol. 24 (33): 5313–27. doi:. PMID 17060676.
- ^ Robertson A, Davidson B (2007). "Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9". European journal of gastroenterology & hepatology 19 (2): 167–9. doi:. PMID 17273004.
- ^ Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981). "Specific antigen in serum of patients with colon carcinoma". Science 212 (4490): 53–5. PMID 6163212.
